Targeting Cancer Cell Ferroptosis to Reverse Immune Checkpoint Inhibitor Therapy Resistance

Area of Science:

• Oncology
• Immunology
• Cell Death Research

Background:

• Immune checkpoint inhibitors (ICIs) have improved outcomes for advanced cancer patients.
• However, many patients exhibit resistance to ICI therapy, necessitating research into underlying mechanisms.
• Regulated cell death (RCD) pathways, particularly ferroptosis, are emerging as critical factors in anti-tumor immunity.

Purpose of the Study:

• To review the clinical applications and outcomes of ICI therapy across various cancers.
• To elucidate the role of ferroptosis as an immunogenic cell death (ICD) in cancer.
• To explore the molecular links between ferroptosis and ICI therapy and its potential to overcome resistance.

Main Methods:

• Literature review of clinical practices and outcomes of ICI therapy.
• Overview of ferroptosis mechanisms and its immunogenic properties.
• Analysis of molecular pathways connecting ferroptosis, interferon-γ signaling, and ICI resistance, including the role of TYRO3.

Main Results:

• ICI therapy has demonstrated significant clinical success but is limited by intrinsic resistance.
• Ferroptosis, a distinct RCD, is immunogenic and can enhance anti-tumor immune responses.
• The interferon-γ pathway links ICI therapy and ferroptosis, with TYRO3 potentially mediating resistance by inhibiting ferroptosis.

Conclusions:

• Ferroptosis induction presents a promising strategy to enhance ICI therapy efficacy and overcome resistance.
• Targeting molecular mechanisms that regulate ferroptosis, such as TYRO3, could reverse resistance to ICI therapy.
• Further research into ferroptosis is crucial for its clinical translation in cancer immunotherapy.